生化失败并非复发性前列腺癌总生存的替代终点:NRG Oncology/RTOG 9601 分析
基于 NRG/RTOG 9601 试验中 760 例前列腺切除术后复发男性,评估生化失败(BF1、BF2)、远处转移(DM)和无转移生存(MFS)作为总生存(OS)替代终点的性能。MFS 与 OS 强相关(τ=0.86,R²=0.67),而 BF1(τ=0.25,R²=0.09)和 BF2(τ=0.40,R²=0.12)相关性弱。结论认为 MFS 是强替代终点,依据生化失败推断生存获益需谨慎。
要点
- MFS 与 OS 强相关(τ=0.86,R²=0.67),可作为复发性前列腺癌的替代终点。
- BF1 和 BF2 与 OS 相关性弱(τ=0.25 和 0.40,R²=0.09 和 0.12),不宜作为替代终点。
- 依据生化失败推断生存获益需谨慎;缺乏合并症数据限制亚组评估。
核心结论
- MFS 是前列腺切除术后复发接受挽救性放疗男性中 OS 的强替代终点。
- 依据生化失败推断生存获益需谨慎。
- 缺乏合并症数据,无法评估无或轻微合并症男性中生化失败能否作为 OS 替代终点。
研究设计与样本
- NRG/RTOG 9601 随机分配 760 例前列腺切除术后复发男性,接受挽救性放疗联合 2 年安慰剂或比卡鲁胺 150 mg 每日。
- 评估的中间临床终点包括 BF1、BF2、DM 和 MFS。
- 采用 Prentice 标准和两阶段荟萃分析方法评估替代性。
主要发现
- BF1、BF2、DM 和 MFS 均满足四项 Prentice 标准。
- 两阶段荟萃分析中,MFS 与 OS 强相关(τ=0.86),DM 与 OS 中度相关(τ=0.66),BF1(τ=0.25)和 BF2(τ=0.40)与 OS 相关性较弱。
- 抗雄激素治疗对 MFS 和 OS 的治疗效应相关(R²=0.67),但对 BF1(R²=0.09)、BF2(R²=0.12)或 DM(R²=0.18)与 OS 不成立。
关键数值与推荐
- BF1 定义:前列腺特异性抗原最低点+0.3-0.5 ng/mL 或开始挽救性激素治疗。
- BF2 定义:前列腺特异性抗原最低点+2 ng/mL。
- MFS 与 OS 的 Kendall τ=0.86,治疗效应 R²=0.67。
- BF1 与 OS 的 τ=0.25,治疗效应 R²=0.09;BF2 与 OS 的 τ=0.40,治疗效应 R²=0.12。
- DM 与 OS 的 τ=0.66,治疗效应 R²=0.18。
临床怎么用
- 作者认为 MFS 是前列腺切除术后复发接受挽救性放疗男性中 OS 的强替代终点。
- 作者提示依据生化失败推断生存获益需谨慎。
局限性
- 缺乏合并症数据,无法评估无或轻微合并症男性中生化失败能否作为 OS 替代终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. MATERIALS AND METHODS: NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average R2 between treatment hazard ratios for ICE and OS). RESULTS: BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated (R2 = 0.67), but this was not true for BF1 (R2 = 0.09), BF2 (R2 = 0.12), or DM (R2 = 0.18) and OS. CONCLUSION: MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.
引用
- Jackson WC, Tang M, Schipper MJ, et al. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. J Clin Oncol. 2022. PMID: 35737923. doi:10.1200/JCO.21.02741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。